文章名稱引用次數(shù)

• MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer59
• Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype24
• If we build it they will come: targeting the immune response to breast cancer17
• Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis16
• 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer15
• Are all cyclin-dependent kinases 4/6 inhibitors created equal?15
• Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer15
• Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy13
• Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer12
• E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer12